{"id":"W4392787310","doi":"10.1136/rmdopen-2023-003855","title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","year":2024,"lang":"en","type":"article","venue":"RMD Open","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"UCB Pharma; National Institute for Health and Care Research","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Placebo; Adverse effect; Psoriasis; Gastroenterology; Rheumatology; Incidence (geometry); Arthritis; Surgery; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003101846,0.0005228848,0.001401061,0.0002306998,0.0002675759,0.0005909601,0.0003988823,0.0007702752,0.002982236],"category_scores_gemma":[0.001870733,0.0003609723,0.0007369824,0.0002492691,0.00033377,0.0005730073,0.0003767496,0.001474541,0.0005191636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003389882,"about_ca_system_score_gemma":0.000718536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001844156,"about_ca_topic_score_gemma":0.0006935767,"domain_scores_codex":[0.9992274,0.0004332294,0.00005319259,0.00008599873,0.000107278,0.00009278316],"domain_scores_gemma":[0.9989358,0.0002361018,0.0003474062,0.0001110895,0.00007647966,0.0002932453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6716096,0.02866146,0.02490029,0.001909274,0.001478598,0.0002502035,0.0002941804,0.00143703,0.0304228,0.0002632405,0.004957728,0.2338157],"study_design_scores_gemma":[0.5217413,0.3756462,0.08610401,0.000208953,0.0006893151,0.0009758947,0.00009185654,0.00200071,0.004979598,0.0002836497,0.007225228,0.00005327414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919409,0.004127897,0.0004754894,0.0003028974,0.00005551266,0.0009125555,0.0005372109,0.00005656939,0.001591002],"genre_scores_gemma":[0.9941907,0.001261472,0.001082442,0.000661012,0.0001069383,0.0008706577,0.0008793843,0.00001169578,0.0009357845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003101846,"threshold_uncertainty_score":0.01640427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05058052042586963,"score_gpt":0.330171936278087,"score_spread":0.2795914158522174,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}